Affini-T

Affini-T Therapeutics is a clinical-stage precision immunotherapy company that unlocks the power of T cells and targets core oncogenic driver mutations, beginning with KRAS, to develop potentially curative therapies for patients with solid tumor cancers. The company is advancing oncogenic-driver programs including TP53 R175H, KRAS G12D, and KRAS G12V, and has presented CRISPR gene-editing and trial-in-progress data at scientific meetings. Affini-T licenses pipeline programs from leading comprehensive cancer centers and focuses on discovery and development of innovative T-cell therapies.